Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Wataru Akita"'
Autor:
Masako Yamamoto, MD, Yuriko Kawase, MD, PhD, Emi Nakajima, MD, PhD, Yoshiaki Matsuura, MD, PhD, Wataru Akita, MD, PhD, Ryousuke Aoki, MD, PhD, Yusuke Suzuki, MD, PhD, Hiroshi Mitsui, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 21, Iss , Pp 150-153 (2022)
Externí odkaz:
https://doaj.org/article/3568c01318554cd2a848dca2f412608f
Autor:
Yuriko Kawase, Hiroshi Mitsui, Yuki Isami, Akari Kondo, Takeshi Matsutani, Wataru Akita, Koji Yasuda
Publikováno v:
The Journal of Dermatology. 47
Autor:
Yasunori Sasaki, Haruna Azetsu, Wataru Akita, Eriko Takehara, Michio Kuwahara, Keita Kusaka, Satomi Shikuma
Publikováno v:
Therapeutic Apheresis and Dialysis. 20:12-19
Cardiovascular events (CVEs) are major complications in patients with chronic kidney disease (CKD). However, few studies have investigated the effects of CVEs on end-stage renal disease (ESRD) and mortality of pre-dialysis patients. We followed 377 C
Autor:
Takashi Oda, Satomi Shikuma, Wataru Akita, Motoko Chiga, Shintaro Mandai, Takayasu Mori, Eriko Takehara, Shinichi Uchida, Michio Kuwahara
Publikováno v:
Internal Medicine
A 55-year-old man developed rapidly progressive glomerulonephritis and nephrotic syndrome. A kidney biopsy specimen showed diffuse proliferative and crescentic glomerulonephritis with monoclonal IgG1κ, humps, and nephritis-associated plasmin recepto
Autor:
Satomi Shikuma, Yoshihiro Mori, Syoko Hasumi, Shintaro Mandai, Tomomi Tanaka, Wataru Akita, Sei Sasaki, Michio Kuwahara
Publikováno v:
Clinical and Experimental Nephrology. 18:755-762
Erythropoiesis-stimulating agents (ESAs) are standard therapy for chronic kidney disease (CKD) patients with renal anemia. However, few studies have compared the effects of different ESAs on anemia in identical pre-dialysis CKD patients.Seventy-nine
Autor:
Susumu Adachi, Yoshihiro Mori, Shinichi Uchida, Michio Kuwahara, Wataru Akita, Satomi Shikuma, Sei Sasaki, Tomoki Asai, Yusuke Tsukamoto, Junichi Ishigami, Yumi Noda, Tatemitsu Rai
Publikováno v:
Therapeutic Apheresis and Dialysis. 16:541-547
Chronic kidney disease (CKD) increases the risk of developing cardiovascular diseases such as heart failure (HF) and ischemic heart disease (IHD). The characteristics of patients with CKD complicated with HF at the time of starting hemodialysis have
Autor:
Soichiro Iimori, Tomokazu Okado, Yusuke Tsukamoto, Junichi Ishigami, Tamaki Kuyama, Wataru Akita, Tsuyoshi Ohnishi, Michio Kuwahara, Satomi Shikuma, Shigeru Takada, Tomoki Asai, Yoshihiro Mori, Sei Sasaki, Masato Tajima
Publikováno v:
Clinical and Experimental Nephrology. 16:930-937
Cause-and-effect associations between sevelamer hydrochloride (HCl) and mortality have yet to be clarified. The effects of sevelamer HCl on mortality, lipid abnormality and arterial stiffness were examined in patients with chronic kidney disease stag
Autor:
Michio, Kuwahara, Eriko, Takehara, Yasunori, Sasaki, Haruna, Azetsu, Keita, Kusaka, Satomi, Shikuma, Wataru, Akita
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 20(1)
Cardiovascular events (CVEs) are major complications in patients with chronic kidney disease (CKD). However, few studies have investigated the effects of CVEs on end-stage renal disease (ESRD) and mortality of pre-dialysis patients. We followed 377 C
Autor:
Sei Sasaki, Susumu Adachi, Soichiro Iimori, Yusuke Tsukamoto, Tomoki Asai, Wataru Akita, Tatemitsu Rai, Yoshihiro Mori, Shinichi Uchida, Michio Kuwahara, Tamaki Kuyama
Publikováno v:
Clinical and Experimental Nephrology. 15:121-125
Anemia is a common complication of patients with chronic kidney disease (CKD), which not only lowers their quality of life but also potentially causes cardiovascular diseases such as congestive heart failure and coronary heart disease, and accelerate
Publikováno v:
The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec). 2018:1P2-L18